Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

First-In-Class Nasacort OTC Also Originates ‘Children’s’ Label

This article was originally published in The Tan Sheet

Executive Summary

Sanofi introduces Children’s Nasacort Allergy 24HR in the same formulation and dosage as the original OTC switch, but with “children’s” added to the package after approval by FDA. The firm promotes the product as the “first and only” 24-hour multi-symptom nasal allergy spray available OTC for children ages 2 and up.


Related Content

Children's Flonase Is Latest Play For Nasal Allergy Spray Market Share
Icy Hot SmartRelief Latest TENS Target Is Back Pain
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
Adulturated red yeast rice
Martek/Mead Agreement


Related Companies